{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:12:56Z","timestamp":1786378376675,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Passive immunization is an effective option for treatment against hand, foot and mouth disease caused by EV71, especially with cross-neutralizing IgG monoclonal antibodies. In this study, an EV71-specific IgG2a antibody designated 5H7 was identified and characterized. 5H7 efficiently neutralizes the major EV71 genogroups (A, B4, C2, C4). The conformational epitope of 5H7 was mapped to the highly conserved amino acid position 74 on VP3 capsid protein using escape mutants. Neutralization with 5H7 is mediated by the inhibition of viral attachment, as revealed by virus-binding and post-attachment assays. In a competitive pull-down assay with SCARB2, 5H7 blocks the receptor-binding site on EV71 for virus neutralization. Passive immunization of chimeric 5H7 protected 100% of two-week-old AG129 mice from lethal challenge with an EV71 B4 strain for both prophylactic and therapeutic treatments. In contrast, 10D3, a previously reported neutralizing antibody that takes effect after virus attachment, could only confer prophylactic protection. These results indicate that efficient interruption of viral attachment is critical for effective therapeutic activity with 5H7. This report documents a novel universal neutralizing IgG antibody for EV71 therapeutics and reveals the underlying mechanism.<\/jats:p>","DOI":"10.1038\/srep46402","type":"journal-article","created":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T09:27:21Z","timestamp":1492594041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity"],"prefix":"10.1038","volume":"7","author":[{"given":"Qiang","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyong","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Tak Kwong","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-I","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Kwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"key":"BFsrep46402_CR1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3345\/kjp.2016.59.10.395","volume":"59","author":"KY Lee","year":"2016","unstructured":"Lee, K. Y. Enterovirus 71 infection and neurological complications. Korean J Pediatr 59, 395\u2013401 (2016).","journal-title":"Korean J Pediatr"},{"key":"BFsrep46402_CR2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3201\/eid1301.020112","volume":"9","author":"KP Chan","year":"2003","unstructured":"Chan, K. P. et al. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9, 78\u201385 (2003).","journal-title":"Emerg Infect Dis"},{"key":"BFsrep46402_CR3","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/00006454-199912000-00013","volume":"18","author":"LY Chang","year":"1999","unstructured":"Chang, L. Y. et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 18, 1092\u20136 (1999).","journal-title":"Pediatr Infect Dis J"},{"key":"BFsrep46402_CR4","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0140-6736(05)60789-1","volume":"352","author":"LC Lum","year":"1998","unstructured":"Lum, L. C., Wong, K. T., Lam, S. K., Chua, K. B. & Goh, A. Y. Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet 352, 1391 (1998).","journal-title":"Lancet"},{"key":"BFsrep46402_CR5","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJM199909233411302","volume":"341","author":"CC Huang","year":"1999","unstructured":"Huang, C. C. et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 341, 936\u201342 (1999).","journal-title":"N Engl J Med"},{"key":"BFsrep46402_CR6","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1128\/JCM.00563-09","volume":"47","author":"F Yang","year":"2009","unstructured":"Yang, F. et al. Enterovirus 71 outbreak in the People\u2019s Republic of China in 2008. J Clin Microbiol 47, 2351\u20132 (2009).","journal-title":"J Clin Microbiol"},{"key":"BFsrep46402_CR7","doi-asserted-by":"crossref","first-page":"38451","DOI":"10.1038\/srep38451","volume":"6","author":"MY Liu","year":"2016","unstructured":"Liu, M. Y. et al. Characterization of enterovirus 71 infection and associated outbreak of Hand, Foot, and Mouth Disease in Shawo of China in 2012. Sci Rep 6, 38451 (2016).","journal-title":"Sci Rep"},{"key":"BFsrep46402_CR8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1586\/14760584.2016.1138862","volume":"15","author":"QY Mao","year":"2016","unstructured":"Mao, Q. Y., Wang, Y., Bian, L., Xu, M. & Liang, Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines 15, 599\u2013606 (2016).","journal-title":"Expert Rev Vaccines"},{"key":"BFsrep46402_CR9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1574-6976.2002.tb00601.x","volume":"26","author":"PC McMinn","year":"2002","unstructured":"McMinn, P. C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26, 91\u2013107 (2002).","journal-title":"FEMS Microbiol Rev"},{"key":"BFsrep46402_CR10","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.3390\/v7122949","volume":"7","author":"Q Ng","year":"2015","unstructured":"Ng, Q., He, F. & Kwang, J. Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines. Viruses 7, 6441\u201357 (2015).","journal-title":"Viruses"},{"key":"BFsrep46402_CR11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nsmb.2255","volume":"19","author":"X Wang","year":"2012","unstructured":"Wang, X. et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19, 424\u20139 (2012).","journal-title":"Nat Struct Mol Biol"},{"key":"BFsrep46402_CR12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.1218713","volume":"336","author":"P Plevka","year":"2012","unstructured":"Plevka, P., Perera, R., Cardosa, J., Kuhn, R. J. & Rossmann, M. G. Crystal structure of human enterovirus 71. Science 336, 1274 (2012).","journal-title":"Science"},{"key":"BFsrep46402_CR13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jviromet.2011.12.015","volume":"180","author":"TK Kiener","year":"2012","unstructured":"Kiener, T. K. et al. Characterization of a monoclonal antibody against the 3D polymerase of enterovirus 71 and its use for the detection of human enterovirus A infection. J Virol Methods 180, 75\u201383 (2012).","journal-title":"J Virol Methods"},{"key":"BFsrep46402_CR14","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1128\/JVI.01019-09","volume":"84","author":"KK Tee","year":"2010","unstructured":"Tee, K. K. et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 84, 3339\u201350 (2010).","journal-title":"J Virol"},{"key":"BFsrep46402_CR15","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2008.03.041","volume":"26","author":"HL Chen","year":"2008","unstructured":"Chen, H. L. et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 26, 2882\u20139 (2008).","journal-title":"Vaccine"},{"key":"BFsrep46402_CR16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1586\/erv.13.18","volume":"12","author":"TK Kiener","year":"2013","unstructured":"Kiener, T. K., Premanand, B. & Kwang, J. Immune responses to baculovirus-displayed enterovirus 71 VP1 antigen. Expert Rev Vaccines 12, 357\u201364 (2013).","journal-title":"Expert Rev Vaccines"},{"key":"BFsrep46402_CR17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7150\/thno.7457","volume":"4","author":"L Xu","year":"2014","unstructured":"Xu, L. et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics 4, 498\u2013513 (2014).","journal-title":"Theranostics"},{"key":"BFsrep46402_CR18","doi-asserted-by":"crossref","first-page":"e55517","DOI":"10.1371\/journal.pone.0055517","volume":"8","author":"F He","year":"2013","unstructured":"He, F. et al. Development of a sensitive and specific epitope-blocking ELISA for universal detection of antibodies to human enterovirus 71 strains. PLoS One 8, e55517 (2013).","journal-title":"PLoS One"},{"key":"BFsrep46402_CR19","doi-asserted-by":"crossref","first-page":"e2895","DOI":"10.1371\/journal.pntd.0002895","volume":"8","author":"TK Kiener","year":"2014","unstructured":"Kiener, T. K., Jia, Q., Meng, T., Chow, V. T. & Kwang, J. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved \u201cknob\u201d region of VP3 protein. PLoS Negl Trop Dis 8, e2895 (2014).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep46402_CR20","doi-asserted-by":"crossref","first-page":"e109391","DOI":"10.1371\/journal.pone.0109391","volume":"9","author":"Z Li","year":"2014","unstructured":"Li, Z. et al. In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PLoS One 9, e109391 (2014).","journal-title":"PLoS One"},{"key":"BFsrep46402_CR21","doi-asserted-by":"crossref","unstructured":"Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V. & Kayser, V. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev (2016).","DOI":"10.1016\/j.addr.2016.11.004"},{"key":"BFsrep46402_CR22","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1128\/JVI.06103-11","volume":"86","author":"WX Khong","year":"2012","unstructured":"Khong, W. X. et al. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86, 2121\u201331 (2012).","journal-title":"J Virol"},{"key":"BFsrep46402_CR23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01315592","volume":"47","author":"HG Bahnemann","year":"1975","unstructured":"Bahnemann, H. G. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol 47, 47\u201356 (1975).","journal-title":"Arch Virol"},{"key":"BFsrep46402_CR24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1743-422X-9-238","volume":"9","author":"T Meng","year":"2012","unstructured":"Meng, T., Kiener, T. K. & Kwang, J. RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production. Virol J 9, 238 (2012).","journal-title":"Virol J"},{"key":"BFsrep46402_CR25","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nm.1992","volume":"15","author":"S Yamayoshi","year":"2009","unstructured":"Yamayoshi, S. et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15, 798\u2013801 (2009).","journal-title":"Nat Med"},{"key":"BFsrep46402_CR26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrmicro974","volume":"2","author":"A Casadevall","year":"2004","unstructured":"Casadevall, A., Dadachova, E. & Pirofski, L. A. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2, 695\u2013703 (2004).","journal-title":"Nat Rev Microbiol"},{"key":"BFsrep46402_CR27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/INF.0b013e3181a41d63","volume":"28","author":"TC Lee","year":"2009","unstructured":"Lee, T. C. et al. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J 28, 904\u201310 (2009).","journal-title":"Pediatr Infect Dis J"},{"key":"BFsrep46402_CR28","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1016\/j.vaccine.2015.10.104","volume":"33","author":"L Jiang","year":"2015","unstructured":"Jiang, L. et al. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. Vaccine 33, 6596\u2013603 (2015).","journal-title":"Vaccine"},{"key":"BFsrep46402_CR29","doi-asserted-by":"crossref","first-page":"e1005454","DOI":"10.1371\/journal.ppat.1005454","volume":"12","author":"X Ye","year":"2016","unstructured":"Ye, X. et al. Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody. PLoS Pathog 12, e1005454 (2016).","journal-title":"PLoS Pathog"},{"key":"BFsrep46402_CR30","first-page":"43","volume":"1","author":"S Ranganathan","year":"2002","unstructured":"Ranganathan, S., Singh, S., Poh, C. L. & Chow, V. T. The hand, foot and mouth disease virus capsid: sequence analysis and prediction of antigenic sites from homology modelling. Appl Bioinformatics 1, 43\u201352 (2002).","journal-title":"Appl Bioinformatics"},{"key":"BFsrep46402_CR31","doi-asserted-by":"crossref","first-page":"10636","DOI":"10.1038\/srep10636","volume":"5","author":"Y Ding","year":"2015","unstructured":"Ding, Y. et al. Characterization of the antibody response against EV71 capsid proteins in Chinese individuals by NEIBM-ELISA. Sci Rep 5, 10636 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep46402_CR32","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1016\/j.vaccine.2015.10.103","volume":"33","author":"YI Kim","year":"2015","unstructured":"Kim, Y. I. et al. Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection. Vaccine 33, 6604\u201310 (2015).","journal-title":"Vaccine"},{"key":"BFsrep46402_CR33","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1128\/JVI.03014-14","volume":"89","author":"Y Tan","year":"2015","unstructured":"Tan, Y., Ng, Q., Jia, Q., Kwang, J. & He, F. A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms. J Virol 89, 3712\u201322 (2015).","journal-title":"J Virol"},{"key":"BFsrep46402_CR34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.antiviral.2014.03.002","volume":"105","author":"F He","year":"2014","unstructured":"He, F., Prabakaran, M., Rajesh Kumar, S., Tan, Y. & Kwang, J. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice. Antiviral Res 105, 143\u201351 (2014).","journal-title":"Antiviral Res"},{"key":"BFsrep46402_CR35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.antiviral.2013.08.003","volume":"100","author":"F He","year":"2013","unstructured":"He, F. et al. Effective intranasal therapeutics and prophylactics with monoclonal antibody against lethal infection of H7N7 influenza virus. Antiviral Res 100, 207\u201314 (2013).","journal-title":"Antiviral Res"},{"key":"BFsrep46402_CR36","first-page":"5717108","volume":"2016","author":"P Wei","year":"2016","unstructured":"Wei, P. et al. Pains and Gains from China\u2019s Experiences with Emerging Epidemics: From SARS to H7N9. Biomed Res Int 2016, 5717108 (2016).","journal-title":"Biomed Res Int"},{"key":"BFsrep46402_CR37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1073\/pnas.97.1.79","volume":"97","author":"Y He","year":"2000","unstructured":"He, Y. et al. Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci USA 97, 79\u201384 (2000).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep46402_CR38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1128\/JVI.01848-13","volume":"88","author":"X Ye","year":"2014","unstructured":"Ye, X. et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 88, 72\u201381 (2014).","journal-title":"J Virol"},{"key":"BFsrep46402_CR39","doi-asserted-by":"crossref","first-page":"e29751","DOI":"10.1371\/journal.pone.0029751","volume":"7","author":"XF Lim","year":"2012","unstructured":"Lim, X. F. et al. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One 7, e29751 (2012).","journal-title":"PLoS One"},{"key":"BFsrep46402_CR40","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","volume":"9","author":"AL Nelson","year":"2010","unstructured":"Nelson, A. L., Dhimolea, E. & Reichert, J. M. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9, 767\u201374 (2010).","journal-title":"Nat Rev Drug Discov"},{"key":"BFsrep46402_CR41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/mab.2013.0080","volume":"33","author":"V Ahmadzadeh","year":"2014","unstructured":"Ahmadzadeh, V., Farajnia, S., Feizi, M. A. & Nejad, R. A. Antibody humanization methods for development of therapeutic applications. Monoclon Antib Immunodiagn Immunother 33, 67\u201373 (2014).","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"BFsrep46402_CR42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF01541346","volume":"14","author":"G Sigounas","year":"1994","unstructured":"Sigounas, G., Harindranath, N., Donadel, G. & Notkins, A. L. Half-life of polyreactive antibodies. J Clin Immunol 14, 134\u201340 (1994).","journal-title":"J Clin Immunol"},{"key":"BFsrep46402_CR43","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1073\/pnas.1320624111","volume":"111","author":"P Plevka","year":"2014","unstructured":"Plevka, P. et al. Neutralizing antibodies can initiate genome release from human enterovirus 71. Proc Natl Acad Sci USA 111, 2134\u20139 (2014).","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep46402.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep46402","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/srep46402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/srep46402.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:55:48Z","timestamp":1671818148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep46402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,6,30]]}},"alternative-id":["BFsrep46402"],"URL":"https:\/\/doi.org\/10.1038\/srep46402","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]},"assertion":[{"value":"15 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46402"}}